
Please try another search
Novo Nordisk (NYSE:NVO) saw a nearly 1% rise in its stock price today after the U.S. Patent Office tribunal rejected challenges to two critical patents for its drugs Wegovy and Ozempic. These challenges were brought by Mylan Pharmaceuticals, a generic drugmaker aiming to produce generic versions of these medications.
Mylan, which is owned by Viatris Inc (NASDAQ:VTRS), had argued that the patents should be invalidated because they were based on the anti-diabetes medication liraglutide. The tribunal denied Mylan's requests to review the Wegovy and Ozempic patents.
Mylan has additionally challenged a third patent connected to a treatment method involving these medications. The board is set to announce its decision on whether to review this patent by Friday. Novo Nordisk said it plans to vigorously defend its intellectual property.
Wegovy, a groundbreaking weight-loss drug, has enjoyed significant sales, leading to predictions by some analysts that the obesity market could surpass $100 billion by the decade's end. Novo's profits from Wegovy and Ozempic have contributed to its status as Europe's most valuable company as of September.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.